Clinical characteristics of patients with AML
Patient no. . | Sex . | Age, y . | FAB category . | CD34 blasts, % . | Karyotype . |
|---|---|---|---|---|---|
| 1 | F | 52 | M1 | 56 | 46 |
| 2 | F | 44 | M1 | 36 | 48,(21) |
| 3 | F | 65 | M4 | 17 | 46,inv(16) |
| 4 | F | 61 | M2 | > 90 | 46 |
| 5 | M | 53 | M4 | 60 | 46 |
| 6 | M | 64 | M2 | > 90 | 46 |
| 7 | M | 35 | M1 | > 90 | 46,del(13)(q13q22) |
| 8 | M | 60 | M4 | > 90 | ND |
| 9 | F | 78 | M1 | > 90 | ND |
| 10 | F | 38 | M2 | 9-35 | 46,t(8;21) |
| 11 | M | 10 | M4 | > 90 | ND |
| 12 | M | 72 | CML/M2 | 80 | 47,(+13) |
| 13 | F | 71 | M4 | 20 | 46 |
| 14 | M | 81 | M2 | 43 | 47,(+11) |
| 15 | F | 62 | M2 | > 90 | 46,t(8;21) |
| 16 | M | 85 | M0 | > 90 | ND |
| 17 | M | 74 | MD | > 90 | ND |
| 18 | M | 38 | M0 | > 90 | ND |
Patient no. . | Sex . | Age, y . | FAB category . | CD34 blasts, % . | Karyotype . |
|---|---|---|---|---|---|
| 1 | F | 52 | M1 | 56 | 46 |
| 2 | F | 44 | M1 | 36 | 48,(21) |
| 3 | F | 65 | M4 | 17 | 46,inv(16) |
| 4 | F | 61 | M2 | > 90 | 46 |
| 5 | M | 53 | M4 | 60 | 46 |
| 6 | M | 64 | M2 | > 90 | 46 |
| 7 | M | 35 | M1 | > 90 | 46,del(13)(q13q22) |
| 8 | M | 60 | M4 | > 90 | ND |
| 9 | F | 78 | M1 | > 90 | ND |
| 10 | F | 38 | M2 | 9-35 | 46,t(8;21) |
| 11 | M | 10 | M4 | > 90 | ND |
| 12 | M | 72 | CML/M2 | 80 | 47,(+13) |
| 13 | F | 71 | M4 | 20 | 46 |
| 14 | M | 81 | M2 | 43 | 47,(+11) |
| 15 | F | 62 | M2 | > 90 | 46,t(8;21) |
| 16 | M | 85 | M0 | > 90 | ND |
| 17 | M | 74 | MD | > 90 | ND |
| 18 | M | 38 | M0 | > 90 | ND |
Samples 1 to 9 and 16 to 18 were obtained at diagnosis; numbers 10 to 15 were patients under treatment.
FAB indicates French-American-British classification; ND, not determined; CML, chronic myeloid leukemia; MD, AML with multilineage dysplasia.